Related Experiment Video
Updated: Jun 23, 2026

Quantification of Breast Cancer Cell Invasiveness Using a Three-dimensional (3D) Model
Published on: June 11, 2014
ERBB1 and ERBB2 have distinct functions in tumor cell invasion and intravasation
Dmitriy Kedrin1, Jeffrey Wyckoff, Pamela J Boimel
1Department of Anatomy and Structural Biology and Gruss-Lipper Biophotonics Center, Albert Einstein College of Medicine, Bronx, New York, USA.
Purpose:
The epidermal growth factor receptor (ERBB1) and related family member HER-2/neu (ERBB2) are often overexpressed in aggressive breast cancers and their overexpression is correlated with poor prognosis. Clinical studies using ERBB inhibitors have focused on tumor growth effects, but ERBBs can contribute to malignancy independent of their effects on tumor growth. Our studies were designed to evaluate the effect of ERBB inhibition on tumor cell motility and intravasation in vivo using clinically relevant small-molecule inhibitors.
Experimental Design:
Using in vivo mouse models of breast cancer, we test the effects of ERBB1 and ERBB2 inhibitors AC480 and lapatinib, ERBB1 inhibitor gefitinib, and ERBB2 inhibitor AG825 on in vivo tumor cell invasive properties in mammary fat pad tumors.
Results:
ERBB1 and ERBB2 inhibition rapidly (within 3 h) inhibits both tumor cell motility and intravasation. Using gefitinib, ERBB1 inhibition rapidly inhibits tumor cell motility and invasion but not intravasation, whereas ERBB2 inhibition by AG825 rapidly blocks intravasation.
Conclusions:
ERBB1 and ERBB2 inhibition can rapidly block tumor cell invasive properties. In addition, we differentiate for the first time the contributions of ERBB1 and ERBB2 to the key metastatic properties of in vivo tumor cell invasion and intravasation. These experiments temporally and molecularly separate two key stages in tumor cell entry into blood vessels: invasion and intravasation. These results indicate that ERBB inhibition should be considered for blocking other tumor cell malignant properties besides growth.
Insights
Epidermal growth factor receptor (EGFR) and HER2 inhibition rapidly blocks breast cancer cell invasion and intravasation. This study differentiates the roles of EGFR and HER2 in metastasis, suggesting ERBB inhibition for broader anti-cancer strategies.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Metastasis
Background:
- Epidermal growth factor receptor (EGFR, also known as ERBB1) and HER2 (ERBB2) are frequently overexpressed in aggressive breast cancers, correlating with poor patient prognosis.
- While ERBB inhibitors are studied for tumor growth effects, ERBBs can promote malignancy independently of tumor growth.
- ERBB signaling pathways play a critical role in cancer cell invasion and metastasis.
Purpose of the Study:
- To investigate the effect of ERBB1 and ERBB2 inhibition on in vivo tumor cell motility and intravasation using clinically relevant small-molecule inhibitors.
- To evaluate the potential of ERBB inhibitors in blocking key steps of cancer cell metastasis beyond tumor growth.
Main Methods:
- Utilized in vivo mouse models of breast cancer, specifically mammary fat pad tumors.
- Tested the effects of ERBB1 and ERBB2 inhibitors, including AC480, lapatinib, gefitinib (ERBB1 inhibitor), and AG825 (ERBB2 inhibitor), on tumor cell invasive properties.
Main Results:
- Inhibition of both ERBB1 and ERBB2 rapidly suppressed tumor cell motility and intravasation within 3 hours.
- ERBB1 inhibition (gefitinib) effectively reduced tumor cell motility and invasion but not intravasation.
- ERBB2 inhibition (AG825) specifically and rapidly blocked intravasation.
Conclusions:
- ERBB1 and ERBB2 inhibition demonstrate rapid efficacy in blocking critical tumor cell invasive properties.
- This study provides the first differentiation of ERBB1 and ERBB2 contributions to in vivo tumor cell invasion and intravasation.
- The findings suggest that ERBB inhibition can be a valuable strategy to impede cancer cell metastasis by targeting invasion and intravasation, in addition to tumor growth.
Related Concept Videos
Mitogens and the Cell Cycle
Cancer Cell Migration through Invadopodia
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Cadherins in Tissue Organization
Cell Sorting During Development
Cell sorting plays an...
